



Goldrea Announces Changes to Subsidiary's Board

July 16, 2019 - Vancouver, British Columbia

CSE:GOR, Frankfurt:GOJ, OTC-US:GORAF

Goldrea Resources Corp. ("Goldrea" or the "Company") announces the appointment of Dr. Terrance Owen as a director of Global Lab Analytics Inc. ("GLA"), the Company's wholly-owned subsidiary.

Since 1980, Dr. Owen has founded and managed several companies in life sciences, including numerous public companies for which he served as a director and/or president. From 2013 to 2017, Dr. Owen was a cofounder, director (2013-2017), CEO (2013 to 2015) and CFO (2015 to 2017) of Champion Pain Care Corporation (CPAI:OTCBB), created in New York to establish a chain of pain management clinics in the USA. From 2000 to 2013, he was the founder, director and president of Avicore Health Inc. (AVCR:TSX-V), originally an infection control company that is now providing natural products & generic pharmaceuticals. Dr. Owen was the founder, director and one-time president of Helix Biotech which manufactured and marketed proprietary medical diagnostic products, provided contract R&D services and became the largest DNA identity testing laboratory in Canada. Helix amalgamated with Intercon Pharma to create Helix BioPharma (HPB:T), where he served as director and president from 1995 to 1998.

Dr. Owen holds a BSc (Biology Dept., Honours, Field: General Biology) from the University of Victoria, an MSc (Biology Dept., Field: Biochemistry) from the University of New Brunswick, a PhD (Zoology Dept., Field: Biochemistry) from the University of British Columbia, and an MBA from Simon Fraser University.

Dr. Owen replaces Chuck Nokes as a director of GLA. Mr. Nokes has resigned from his position as director and president of GLA, and James Elbert has been appointed to act as interim president of the company.

"It is with great pleasure that I welcome Dr. Owen to the board of Global Lab Analytics," says James Elbert, President and CEO of Goldrea. "Terry's résumé speaks for itself. His experience both in life sciences and public companies will be a tremendous asset to GLA as it continues with the development of its new testing lab in Irvine, California."

For more information, please contact:

James Elbert, President and CEO

Telephone: (604) 559-7230

Email: jelbert@goldrea.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements", which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.